GlassScriptPhysician profile
Jian Shan
NPI 1134481427
$2,008.09
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $91.98 · 2021: $197 · 2022: $690 · 2023: $535 · 2024: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $851.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $443.34 | 2019-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $375.94 | 2022-2024 | |
| Pfizer INC. | $191.08 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $164.57 | 2020-2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $117.29 | 2020-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $103.56 | 2021-2023 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $96.74 | 2019-2023 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $74.07 | 2019-2021 | |
| Esperion Therapeutics, INC. | $71.74 | 2021-2023 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.03 | 2020-2023 | Jardiance |
| Edwards Lifesciences Corporation | $63.52 | 2019-2023 | Sapien 3 Ultra Resilia |
| Novo Nordisk INC | $63.13 | 2023-2024 | Ozempic, Rybelsus |
| Kestra Medical Technology Services, INC. | $48.01 | 2024 | Assure Wcd |
| Kiniksa Pharmaceuticals, LTD. | $38.55 | 2022-2023 | Arcalyst |
| Genzyme Corporation | $25.82 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $22.91 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $18.58 | 2019 | |
| Alnylam Pharmaceuticals INC. | $18.21 | 2024 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jian Shan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.